- ISIN
- US74587B1017
- CUSIP
- 74587B101
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- IPO Date
- May 18, 2016
Highlights
- Market Cap
- $2.43B
- Enterprise Value
- $2.37B
- EPS (TTM)
- -$1.10
- Total Revenue (TTM)
- $751.00K
- Gross Profit (TTM)
- -$684.00K
- EBITDA (TTM)
- -$73.79M
- Year Range
- $12.56 - $36.79
- Target Price
- $30.00
- ROA (TTM)
- -91.36%
- ROE (TTM)
- -112.47%
- Avg. Volume (1M)
- 355K
- Avg. Volume Value (1M)
- $10.96M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PLSE Performance Chart
Pulse Biosciences, Inc. (PLSE) is up 155.9% since the beginning of the year. At $35 per share, PLSE is trading 4.5% below its 52-week high of $37. Investors who bought $1,000 worth of PLSE shares 5 years ago would now be looking at an investment worth $1,713.
Loading charts...
Compare this symbol against anything
Returns By Period
Pulse Biosciences, Inc. (PLSE) has returned 155.86% so far this year and 138.17% over the past 12 months. Looking at the last ten years, PLSE has achieved an annualized return of 22.44%, outperforming the S&P 500 Index benchmark, which averaged 13.26% per year.
Pulse Biosciences, Inc.
- 1D
- 0.26%
- 1M
- 20.29%
- 6M
- 154.01%
- YTD
- 155.86%
- 1Y
- 138.17%
- 3Y*
- 68.45%
- 5Y*
- 11.37%
- 10Y*
- 22.44%
- ALL TIME*
- 23.35%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
PLSE Monthly Returns History
Based on dividend-adjusted daily data since May 18, 2016, PLSE's average daily return is +0.24%, while the average monthly return is +4.94%. At this rate, an investment would double in approximately 1.2 years.
Historically, 50% of months were positive and 50% were negative. The best month was Feb 2017 with a return of +105.2%, while the worst month was Feb 2022 at -58.2%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 10 months.
On a daily basis, PLSE closed higher 48% of trading days. The best single day was Feb 6, 2026 with a return of +51.6%, while the worst single day was Feb 8, 2022 at -34.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.73% | 35.43% | 15.27% | -1.95% | 18.09% | 10.92% | 26.69% | 155.86% | |||||
| 2025 | 20.22% | -12.52% | -12.12% | 5.78% | 1.67% | -12.80% | -0.46% | 3.46% | 13.90% | -4.35% | -19.14% | 0.29% | -21.14% |
| 2024 | -27.45% | 11.26% | -11.84% | -15.38% | 56.72% | -3.12% | 33.69% | 24.60% | -5.90% | -0.63% | 22.78% | -18.64% | 42.24% |
| 2023 | 13.00% | -12.78% | 23.08% | 91.67% | -3.73% | 15.97% | 9.87% | -40.38% | -14.44% | 12.16% | 99.78% | 35.55% | 341.88% |
| 2022 | -17.89% | -58.22% | -4.33% | -48.56% | -10.80% | -31.39% | 1.96% | -18.59% | 81.10% | -8.26% | -5.21% | 38.50% | -81.30% |
| 2021 | 43.13% | -14.35% | -19.04% | -18.67% | -6.33% | -9.09% | 25.00% | 26.34% | -16.60% | -2.36% | -3.75% | -27.04% | -37.93% |
Benchmark Metrics
Pulse Biosciences, Inc. has an annualized alpha of 55.52%, beta of 1.21, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since May 18, 2016.
- This stock captured 187.04% of S&P 500 Index gains and 141.89% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 55.52%
- Beta
- 1.21
- R²
- 0.06
- Upside Capture
- 187.04%
- Downside Capture
- 141.89%
Return for Risk
Risk / Return Rank
PLSE ranks 88 for risk / return — above 88% of stocks peers on PortfoliosLab. Its historical combined result is among the stronger results in the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Pulse Biosciences, Inc. (PLSE) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PLSE | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.12 | ||
| Sortino ratioReturn per unit of downside risk | +0.77 | ||
| Omega ratioGain probability vs. loss probability | 1.33 | 1.25 | +0.07 |
| Calmar ratioReturn relative to maximum drawdown | 3.69 | 2.00 | +1.69 |
| Martin ratioReturn relative to average drawdown | 7.36 | 8.49 | -1.13 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Pulse Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Pulse Biosciences, Inc. was 97.22%, occurring on Aug 30, 2022. The portfolio has not yet recovered.
The current Pulse Biosciences, Inc. drawdown is 20.65%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-97.22%Aug 2022 | 1y 6mo | — | 5y 5moFeb 2021 - now | Bear market2022 |
-86.09%Mar 2020 | 2y 9mo | 10mo 25d | 3y 7moJun 2017 - Feb 2021 | COVID crash2020 |
-47.35%Apr 2017 | 7d | 2mo 11d | 2mo 18dMar 2017 - Jun 2017 | — |
-18.97%Dec 2016 | 2mo 29d | 18d | 3mo 17dSep 2016 - Dec 2016 | — |
-10.88%Feb 2017 | 4d | 6d | 10dFeb 2017 - Mar 2017 | — |
Drawdown Indicators
| PLSE | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.22% | -56.78% | -40.44% |
Max Drawdown (1Y)Largest decline over 1 year | -36.51% | -9.10% | -27.41% |
Max Drawdown (3Y)Largest decline over 3 years | -54.06% | -18.90% | -35.16% |
Max Drawdown (5Y)Largest decline over 5 years | -95.38% | -25.43% | -69.95% |
Max Drawdown (10Y)Largest decline over 10 years | -97.22% | -33.92% | -63.30% |
Current DrawdownCurrent decline from peak | -20.65% | -1.58% | -19.07% |
Average DrawdownAverage peak-to-trough decline | -59.36% | -10.70% | -48.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.27% | 2.14% | +16.13% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Pulse Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Pulse Biosciences, Inc. is priced in the market compared to other companies in the Medical Instruments & Supplies industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for PLSE relative to other companies in the Medical Instruments & Supplies industry. Currently, PLSE has a P/S ratio of 3,158.6. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PLSE in comparison with other companies in the Medical Instruments & Supplies industry. Currently, PLSE has a P/B value of 35.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PLSE
Add Pulse Biosciences, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PLSE